Zusammenfassung
In den letzten Jahren gab es zunehmend Hinweise, dass die frühzeitige Behandlung der entzündlich rheumatischen Erkrankungen von besonderer Bedeutung für den weiteren Verlauf und die Prognose ist. Da rheumatische Beschwerden sehr häufig sind und der Hausarzt nicht jeden Patienten zum Rheumatologen überweisen kann, sind in einigen Fällen Screening-Untersuchungen hilfreich. Im Rahmen der medikamentösen Therapie der entzündlich rheumatischen Erkrankungen werden zur Zeit vier wesentliche Substanzklassen entweder allein oder in Kombination eingesetzt: Nichtsteroidale Antiphlogistika, Glukokortikoide, Basistherapeutika (krankheitskontrollierende Medikamente) sowie die neue Substanzklasse der Biologika.
Summary
In recent years, evidence has been accumulating that early treatment of inflammatory rheumatic diseases has a particular impact on its further course. Since rheumatic complaints are very common, and the family doctor cannot refer all his patients to a rheumatologist, screening examinations may be helpful in some cases. With regard to medicinal treatment of inflammatory rheumatic diseases, four major classes of drug are currently employed, either alone or in combination: nonsteroidal anti-inflammatory drugs, glucocorticoids, basic drugs (Basistherapeutika = disease-modifying anti-rheumatic drugs), and the new class of biological substances.
Literatur
-
1 De Vries-Bouwstra JK. et al. .EULAR 2005
-
2
Grigor C. et al. .
Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial.
Lancet.
2004;
364
263-269
-
3 da Silva JA. et al. .Low-dose glucocorticoid therapy in rheumatoid arthritis. A review on safety: published evidence and prospective trial data. Ann Rheum Dis 2005
-
4 Zochling J. et al. .ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2005
-
5 Braun J. et al. .First Update of the International ASAS Consensus Statement for the Use of Anti-TNF Agents in Patients with Ankylosing Spondylitis. Ann Rheum Dis 2005
-
6
Boers M, Dijkmans B, Gabriel S, Maradit-Kremers H, O'Dell J, Pincus T.
Making an impact on mortality in rheumatoid arthritis: targeting cardiovascular comorbidity.
Arthritis Rheum.
2004;
50
1734-1739
-
7
Krause D, Schleusser B, Herborn G, Rau R.
Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis.
Arthritis Rheum.
2000;
43
14-21
-
8
Puolakka K, Kautiainen H, Mottonen T. et al. .
Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized followup trial.
Arthritis Rheum.
2004;
50
55-62
Anschrift des Verfassers
Prof. Dr. med. Jürgen Braun
Rheumazentrum Ruhrgebiet
St. Josefs-Krankenhaus
Landgrafenstraße 15
44652 Herne
